DDI Predict

Key features

• DDI prediction using multiple CYP and/or UGT pathways
• Prediction of fraction metabolized (fm) (IVIVE Scaling factors: RAF, Abundance ISEF)
• Gut inhibition using a Model Predicted method
• Prediction of Fg using the Well-Stirred model, Qg and fug
• fu(mic) prediction (Austin or Huston methods)
• kabs prediction (First absorption rate model)
• CI_H prediction (Well-Stirred model and INVIVE Scaling factors)
• Export: filtering capabilities, input values, AUC ratio prediction
• Results: DDI prediction statistics: Min, Max, Mean, Median SD, 5th-95th percentile

Uses

DMPK and GMPK specialists can use this new edition to:

• Improve decision making during drug discovery and development
• Prioritize phase I studies and determine potential contra-indication in phase II/III
• Compare other marketed drugs in the same indication

Key benefits

• Rapid and accurate assessment of DDIs
• Accurately predict DDIs between drug candidates and a large panel of marketed and withdrawn drugs
• Use resulting predictions for risk assessment during the drug approval process
• Investigate DDIs towards potential co-administered drug (therapeutic class) for a given interaction

In vitro and In vivo experimental data from the ADME Database

• DDI Predict draws from an extensive library containing more than 7,000 inhibition and more than 8,000 PK data points measured on 1,500 marketed drugs and withdrawn drugs
• Data extracted from the ADME database comprises experimental data from over 25,000 compounds, 3,500 metabolites, 365,000 biological data analyzed from more than 11,000 scientific journals and FDA documents